AU2014294548B2 - Formulation comprising a hypolipidemic agent - Google Patents

Formulation comprising a hypolipidemic agent Download PDF

Info

Publication number
AU2014294548B2
AU2014294548B2 AU2014294548A AU2014294548A AU2014294548B2 AU 2014294548 B2 AU2014294548 B2 AU 2014294548B2 AU 2014294548 A AU2014294548 A AU 2014294548A AU 2014294548 A AU2014294548 A AU 2014294548A AU 2014294548 B2 AU2014294548 B2 AU 2014294548B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
formula
sodium
formulation
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2014294548A
Other languages
English (en)
Other versions
AU2014294548A1 (en
Inventor
Prakash DAVADRA
Jitendre D. Patel
Snehal Patel
Shafiq Sheikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AU2014294548A1 publication Critical patent/AU2014294548A1/en
Application granted granted Critical
Publication of AU2014294548B2 publication Critical patent/AU2014294548B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014294548A 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent Expired - Fee Related AU2014294548B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2470/MUM/2013 2013-07-25
IN2470MU2013 IN2013MU02470A (enExample) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (2)

Publication Number Publication Date
AU2014294548A1 AU2014294548A1 (en) 2015-12-17
AU2014294548B2 true AU2014294548B2 (en) 2017-08-10

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014294548A Expired - Fee Related AU2014294548B2 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Country Status (21)

Country Link
US (2) US9610277B2 (enExample)
EP (1) EP3024446A1 (enExample)
JP (1) JP2016523895A (enExample)
KR (1) KR101786843B1 (enExample)
CN (1) CN105407873A (enExample)
AP (1) AP2015008876A0 (enExample)
AR (1) AR097067A1 (enExample)
AU (1) AU2014294548B2 (enExample)
BR (1) BR112015031878A2 (enExample)
CA (1) CA2917923A1 (enExample)
EA (1) EA201690072A1 (enExample)
HK (1) HK1219222A1 (enExample)
IN (1) IN2013MU02470A (enExample)
MA (1) MA38865A1 (enExample)
MX (1) MX374628B (enExample)
NZ (1) NZ714558A (enExample)
PH (1) PH12015502802A1 (enExample)
SG (1) SG11201509798PA (enExample)
TW (1) TW201545773A (enExample)
WO (1) WO2015011730A1 (enExample)
ZA (1) ZA201508682B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8149178B2 (en) 2006-05-23 2012-04-03 Intel Corporation Millimeter-wave communication system with directional antenna and one or more millimeter-wave reflectors
RS54735B1 (sr) 2011-01-31 2016-10-31 Cadila Healthcare Ltd Tretman za lipodistrofiju
EA201592020A1 (ru) 2013-04-22 2016-05-31 Кадила Хелзкэр Лимитед Новая композиция для неалкогольной жировой болезни печени (нажбп)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Limited composição farmacêutica e método para o tratamento de colangite biliar primária
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
WO2014174524A1 (en) * 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP1000938A1 (en) 1992-07-03 2000-05-17 Smithkline Beecham Plc Heterocyclic compounds as pharmaceuticals
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
KR100380875B1 (ko) 1995-04-28 2003-10-10 다이이찌 세이야꾸 가부시기가이샤 펜타사이클릭화합물
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU1198699A (en) 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP4213385B2 (ja) 2000-01-19 2009-01-21 カディラ ヘルスケア リミティド 低脂血、低コレステロール血活性を有する新規化合物、それらの製造方法ならびにそれらを含有する製剤組成物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
WO2007097386A1 (ja) * 2006-02-22 2007-08-30 Eisai R & D Management Co., Ltd. 安定化医薬組成物
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
DK2641596T3 (en) 2009-11-26 2018-08-06 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for the treatment of liver disorders
BR112013008985A2 (pt) * 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
WO2014174524A1 (en) * 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bharate et al, "Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review", Journal of Excipients and Food Chemistry (2010), Vol. 1, No. 3, Pages 3-26 *

Also Published As

Publication number Publication date
EA201690072A1 (ru) 2016-06-30
CN105407873A (zh) 2016-03-16
AP2015008876A0 (en) 2015-11-30
NZ714558A (en) 2017-02-24
MX374628B (es) 2025-03-06
BR112015031878A2 (pt) 2017-07-25
CA2917923A1 (en) 2015-01-29
TW201545773A (zh) 2015-12-16
US9610277B2 (en) 2017-04-04
US10098868B2 (en) 2018-10-16
EP3024446A1 (en) 2016-06-01
KR20160013150A (ko) 2016-02-03
KR101786843B1 (ko) 2017-10-18
IN2013MU02470A (enExample) 2015-06-26
WO2015011730A1 (en) 2015-01-29
SG11201509798PA (en) 2016-02-26
MA38865A1 (fr) 2017-12-29
MX2015016971A (es) 2016-04-25
US20170266158A1 (en) 2017-09-21
HK1219222A1 (zh) 2017-03-31
AU2014294548A1 (en) 2015-12-17
JP2016523895A (ja) 2016-08-12
AR097067A1 (es) 2016-02-17
ZA201508682B (en) 2017-03-29
US20160136131A1 (en) 2016-05-19
PH12015502802A1 (en) 2016-03-14

Similar Documents

Publication Publication Date Title
AU2014294548B2 (en) Formulation comprising a hypolipidemic agent
US20090281136A1 (en) Prasugrel pharmaceutical formulations
CA2662265A1 (en) Imatinib compositions
NZ242271A (en) Medicaments containing a vitamin d compound stabilised by a basic substance
CA2904416A1 (en) Stabilization of moisture-sensitive drugs
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
JPWO2009123169A1 (ja) アミド誘導体含有医薬組成物
OA17603A (en) Formulation comprising a hypolipidemic agent.
EP1965773B1 (en) Oral formulation of anhydrous olanzapine form i
US9775832B2 (en) Pharmaceutical composition for oral administration
JP7355846B2 (ja) 固形製剤
EP4260848A1 (en) Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
US11452722B2 (en) Stable pharmaceutical compositions comprising lenalidomide
US12496293B2 (en) Solid pharmaceutical preparation
JPWO2003059337A1 (ja) ２，２−ジクロロ−１２−（４−クロロフェニル）−ドデカン酸含有医薬組成物
JPWO2007046411A1 (ja) イソキサゾール化合物の安定化方法
EA045037B1 (ru) Фармацевтические составы ингибиторов индоламин-2,3-диоксигеназы
WO2006008757A2 (en) Stabilized pharmaceutical compositions of pravastatin
CZ2005141A3 (cs) Lécivý prípravek na bázi amlodipin-besilátu se zvýsenou stabilitou

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee